Livzon Pharmaceutical Group (1513) Financial Statements

Compare

1 Followers

Livzon Pharmaceutical Group Financial Overview

Livzon Pharmaceutical Group's market cap is currently HK$30.86B. The company's EPS TTM is HK$0.4189382757; its P/E ratio is 11.61; and it has a dividend yield of 4.09%. Livzon Pharmaceutical Group is scheduled to report earnings on March 24, 2026, and the estimated EPS forecast is HK$0.86. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Income Statement
Total Revenue	¥ 11.60B	¥ 11.81B	¥ 12.43B	¥ 12.63B	¥ 12.06B
Gross Profit	¥ 7.43B	¥ 7.73B	¥ 7.66B	¥ 8.17B	¥ 7.81B
Operating Income	¥ 2.56B	¥ 2.84B	¥ 2.42B	¥ 2.35B	¥ 2.27B
EBITDA	¥ 3.10B	¥ 3.47B	¥ 3.33B	¥ 3.08B	¥ 2.77B
Net Income	¥ 1.97B	¥ 2.06B	¥ 1.95B	¥ 1.91B	¥ 1.78B
Balance Sheet
Cash & Short-Term Investments	¥ 10.93B	¥ 10.92B	¥ 11.41B	¥ 10.52B	¥ 9.33B
Total Assets	¥ 24.00B	¥ 24.46B	¥ 25.04B	¥ 24.86B	¥ 22.37B
Total Debt	¥ 3.85B	¥ 3.93B	¥ 3.48B	¥ 3.62B	¥ 2.69B
Net Debt	¥ -5.46B	¥ -6.89B	¥ -7.84B	¥ -6.79B	¥ -6.45B
Total Liabilities	¥ 8.20B	¥ 9.55B	¥ 10.28B	¥ 9.93B	¥ 8.06B
Stockholders' Equity	¥ 13.89B	¥ 13.86B	¥ 14.04B	¥ 13.88B	¥ 13.00B
Cash Flow
Free Cash Flow	¥ 2.54B	¥ 2.41B	¥ 2.43B	¥ 1.83B	¥ 593.23M
Operating Cash Flow	¥ 3.10B	¥ 2.98B	¥ 3.25B	¥ 2.77B	¥ 1.90B
Investing Cash Flow	¥ -3.67B	¥ -660.33M	¥ -708.37M	¥ -1.23B	¥ -1.88B
Financing Cash Flow	¥ -2.62B	¥ -2.49B	¥ -1.66B	¥ -720.36M	¥ -815.02M

Currency in CNY

Livzon Pharmaceutical Group Earnings and Revenue History

Income Statement >

Livzon Pharmaceutical Group Debt to Assets

Balance Sheet >

Livzon Pharmaceutical Group Cash Flow

Cash Flow >

Livzon Pharmaceutical Group Forecast EPS vs Actual EPS

Earnings >